Author

S. Durgam

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Sep 2026

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind Trial.

Objective: Anxious distress is associated with poor outcomes in the treatment of major depressive disorder (MDD). This exploratory post hoc analysis utilized data from a phase 3 study to investigate adjunctive lumateperone 42 mg efficacy in patients with MDD with inadequate antidepressant therapy (ADT) response and anx...

Gary S. Sachs, S. Durgam, W. Earley et al. · Journal of Clinical Psychiat... · 0 citations

Open access Sep 2026

250. Efficacy of adjunctive lumateperone 42 mg treatment across patient-reported depression symptoms in major depressive disorder

Abstract Background Patient-reported outcomes are increasingly used as endpoints in clinical trials, as they offer a unique perspective about symptoms and ensure comprehensive treatment assessment. Because patients with major depressive disorder (MDD) often experience persistent depression symptoms, a treatment for MDD...

W. Earley, S. Durgam, R. Migliore et al. · International Journal of Neu... · 0 citations

Open access Sep 2026

193. Efficacy and safety of adjunctive lumateperone 42 mg in major depressive disorder: pooled analysis of demographic and clinical subgroups from Phase 3 randomized placebo-controlled trials

Abstract Background Major depressive disorder (MDD) presents with highly variable clinical symptoms and treatment responses. Patient characteristics can impact treatment outcomes, making it essential to evaluate efficacy across subgroups to establish consistency of treatment effects. Lumateperone is an FDA-approved ant...

W. Earley, S. Durgam, C. Chen et al. · International Journal of Neu... · 0 citations